Chemomab Therapeutics Shareholders Approve Compensation, CEO Terms, Share Plan, and Auditor at 2021 Meeting

Chemomab Therapeutics Ltd.

Proposal 1: Compensation Policy approved with 103,259,980 votes for (99.5%), meeting Israeli Companies Law requirements for non-controlling shareholders.
Proposal 2: Amendment to CEO Dr. Adi Mor's engagement terms approved with 103,495,100 votes for (99.7%), satisfying requisite majority.
Proposal 3: Share incentive plan increase by 540,000 ADSs (10,800,000 ordinary shares) approved with 103,184,280 votes for.
Proposal 4: Reappointment of Somekh Chaikin (KPMG) as independent auditors approved with 103,862,300 votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.